Bristol-Myers Squibb Commits to Global Impact Partnership and Site Advocacy Group

Ellicott City, M.D., June 10, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year partnership with Bristol-Myers Squibb, a leading global biopharmaceutical company. Bristol-Myers Squibb will participate as a Global Impact Partner (GIP), a relationship indicative of Bristol-Myers Squibb’s dedication to promoting greater site sustainability across the global clinical research landscape. Bristol-Myers Squibb will also host a Site Advocacy Group.

“Bristol-Myers Squibb’s partnership with SCRS illustrates their commitment to encouraging collaboration and dialogue amongst industry stakeholders,” comments Christine Pierre, SCRS President. “SCRS is proud to welcome Bristol-Myers Squibb to our community, and applauds their desire to actively listen to the sites’ voice through their partnership and Site Advocacy Group.”

“As a company dedicated to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases, we recognize the critical role clinical research sites play as collaborators in fulfilling this mission,” said Paul Biondi, senior vice president of R&D Operations, Bristol-Myers Squibb. “We look forward to partnering with SCRS as an organization representing the collective voice of clinical research sites from across the world.”

As a GIP, Bristol-Myers Squibb will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council in the development and execution of strategic initiatives for SCRS.